Prostacyclin (PGI2) has been reported to stimulate activities of acid cholesteryl ester hydrolase (ACEH; EC 3.1.1.13) and neutral cholesteryl ester hydrolase (NCEH; EC 3.1.1.13) in the smooth muscle cells leading to a decrease in intracellular cholesteryl ester. Recently, we have found that the half-life of PGI2 was prolonged through stabilization by HDL. HDL is known to have anti-atherogenic properties, although its precise mechanism has not been fully clarified. We therefore hypothesized that HDL can exert anti-atherogenic action by augmenting PGI2-stimulated increases in the activities of ACEH and NCEH. After incubation with PGI2 and HDL, a cell homogenate was made from which the activities of ACEH and NCEH were assessed. HDL significantly augmented the PGI2-induced increase in the activities of both enzymes. This effect of HDL was abolished in the absence of PCI2. Elevated intracellular levels of cyclic AMP were maintained for longer periods by HDL. The increase in both intracellular cyclic AMP levels and enzyme activities disappeared in the presence of an inhibitor of adenylate cyclase, 2'5'-dideoxyadenosine. Radiolabeled smooth muscle cells demonstrated a significant loss in total cholesterol and cholesteryl ester after treatment with PGI2 and HDL, due to the increase in cholesteryl ester hydrolytic activities. These data suggest that HDL enhanced the PGI2-stimulated hydrolysis of cholesteryl ester and augmented the PG12-induced reduction of cellular cholesteryl ester content by stabilizing
Introduction
During the progression of human atherosclerosis, cholesteryl ester (CE)' accumulates in arterial smooth muscle cells (1, 2) . This lipid accumulation can result from inadequate CE hydrolysis and/or enhanced endocytosis of low density lipoproteincholesteryl esters. 1 . Abbreviations used in this paper: ACAT, acyl CoA: cholesterol-Oacyltransferase; ACEH and NCEH, acid and neutral cholesteryl ester hydrolase; ASA, acetylsalicylic acid; CE, cholesteryl ester; cLDL, cationized LDL; DDA, dideoxyadenosine; ETYA, eicosatetraynoic acid; IBMX, 3-isobuthyl-l-methylxanthine; PGI2, prostacyclin; SMC, smooth muscle cell.
There are several enzymes participating in the regulation of cholesterol/cholesteryl ester balance in cells, lysosomal (acid) and cytosolic (neutral) CE hydrolase (ACEH, NCEH; EC 3.1.1.13), which hydrolyze CE, and microsomal acyl CoA: cholesterol-O-acyltransferase (ACAT; EC 2.3.1.26), which esterifies cholesterol. It has been reported that PGI2 stimulates cholesteryl ester hydrolysis within smooth muscle cells. PGI2 increases ACEH and NCEH activities, raising the intracellular levels of cAMP (3, 4) . PGI2 has no effect on ACAT activity (3, 4) . HDL is known to be antiatherogenic (5) (6) (7) (8) . We have recently demonstrated that apolipoprotein A-I, a main constituent protein of HDL, stabilizes PGI2 in the blood (9) . PGI2 is stabilized by HDL-associated apolipoprotein A-I, but not by free apolipoprotein A-I (10) . Therefore, these findings raise the possibility that HDL enhances PGI2-induced lysosomal and cytosolic cholesteryl ester hydrolase activation and the reduction of cellular CE content by stabilizing PGI2. This study was performed to prove this hypothesis. We present herein data showing that PGI2 with HDL can significantly maintain high levels of intracellular cAMP in cultured intact arterial smooth muscle cells (SMC), and that this enhancement of cAMP causes a concomitant increase in the activities of ACEH and NCEH, leading to a reduction in the cellular content of cholesteryl ester.
Methods
Materials. Cholesteryl oleate, oleic acid, 3-isobuthyl- 1 (15) . Dioxane (0.1 ml) containing succinic anhydride and triethylamine was added to 0.1 ml of a sample in order to succinylate cyclic nucleotides in the sample. After 10 min, the mixture was diluted with 0.8 ml of 0.3 M imidazole buffer (pH 6.5). After being kept at 4°C overnight, the unbound radioactive nucleotide was absorbed by dextran-coated charcoal. The radioactivity in the supernatant containing the antibody-bound radioactive nucleotide was counted in a gamma counter (Gamma 5500; Beckman Instruments Inc.).
Preparation of cell homogenates. Cell monolayers were washed twice in 250 mM sucrose containing 1 mM EDTA and 10 mM Tris-HCI, pH 7.0. Cells were then harvested by a rubber policeman, homogenized in 0.5 ml ofthe same buffer, disrupted with 15 
Results
Cultured bovine smooth muscle cells were incubated with PGI2 for the indicated times and cell homogenates were made, from which the activities ofACEH and NCEH were assessed as described in Methods. As shown in Fig. 1 , the activities of ACEH and NCEH increased with the incubation time. They reached a peak at 120 min and then declined to nearly basal levels by 180 min. The addition of HDL (50 mg/dl as cholesterol) to the incubation mixture significantly (P < 0.05) increased the activities without changing the time of peak activity. In the following experiments, peak activities at 120 min were used.
Preincubation with PGI2 caused a dose-dependent increase in the activity of ACEH and NCEH isolated from SMC. The activity of the enzymes was significantly enhanced with the addition of HDL in the presence of ASA (Fig. 2) . This effect was also observed in the pretreatment of ETYA, a dual cyclooxygenase and lipoxygenase inhibitor (23) (data not shown).
To investigate the effects of HDL on PGI2-stimulated enzyme activation, HDL was given simultaneously with PGI2. As shown in Fig. 3 , HDL increased the activities of both enzymes in a dose-dependent manner. The elevation of the en- zyme activity was nearly maximal around 50 mg/dl of HDL. In these experiments, PGI2 was used at the concentration where the enzyme activity increased by -50% (10 and 40 nM for ACEH and NCEH, respectively). In the absence of PGI2, HDL did not increase the activity of either enzyme (Fig. 3) . Enzyme activities were determined after the incubation with PGI2, at the concentrations indicated in Fig. 2 , in the presence or absence of HDL (50 mg/dl as cholesterol). This level of HDL was chosen for the experiment because it evoked a nearly maximal response at 10 nM PGI2 (Fig. 3) . As shown in Fig. 2 , HDL significantly shifted the dose-response curves upward. Thus, HDL was found to augment PGI2-stimulated CE hydrolysis.
We have already demonstrated that HDL is a serum factor that can stabilize an unstable PGI2 (9) . Under the present experimental conditions, we confirmed that HDL prolonged the half-life of PGI2 from 5 to 26 min (Fig. 4) . The prolongation of the PGI2 half-life was not seen with either LDL or VLDL. These results suggest that the effect on PGI2 is specific to HDL (Fig. 4) .
It is known that PGI2 enhances CE hydrolase activity through the elevation of intracellular cyclic AMP levels. It is expected that augmentation of PGI2-induced enzyme activation by HDL is also mediated through the cyclic AMP pathway. Therefore, we investigated the effect of HDL on the intracellular cAMP levels. Cyclic AMP levels rose markedly after incubation with PGI2 and reached a peak at 15 min. Then, they declined progressively and reached near basal levels by 120 min (Fig. 5, closed circles) . On the other hand, in the presence of HDL the cyclic AMP levels remained elevated at 120 min, although the peak levels did not increase furthermore (Fig. 5, open circles) . These data suggest that the augmentation of the PGI2-induced increase in CE hydrolytic activities by HDL depends on the enhancement of intracellular cAMP levels. To further confirm this point, an adenylate cyclase inhibitor, DDA, was employed to suppress the production of intracellular cyclic AMP. Cultured SMC were pretreated with DDA and incubated with PGI2 in the presence or absence of HDL. As illustrated in Fig. 6 , DDA treatment abolished the PGI2-stimulated increases in ACEH and NCEH activities either in the presence or absence of HDL. When DDA was added to the assay mixture after preparation of the enzyme, it did not alter the activity of either enzyme (data not shown). These data indicate that enhancement of enzyme activity strictly depends on intracellular cyclic AMP levels.
The cellular cholesterol level was examined after 24 h of PGI2 and/or HDL treatment using cultured rabbit SMC to determine whether or not increased activity ofcholesteryl ester hydrolases could alter the cellular content. The SMC cholesterol pool was labeled by exposure to cLDL containing [3H]-cholesteryl linoleate. Then, cells were incubated in serum free-DMEM or medium containing PGI2 and/or HDL. HDL progressively decreased the cellular content of both [3H]cholesteryl ester and total [3H]cholesterol. On the other hand, PGI2 caused a reduction in [3H]cholesteryl ester alone. This is considered to be due to the absence of cholesterol acceptors in the media. In the presence of both PGI2 and HDL, the reductions in the cellular content of [3H]cholesteryl ester and total [3H]cholesterol were greater than the combined reduction induced by each substance (Table I) .
Discussion
Population studies have shown an inverse correlation between plasma HDL levels and the incidence and prevalence of atherosclerosis (5) (6) (7) (8) . This suggests that HDL is an anti-atherogenic factor. HDL is considered to exert its anti-atherogenic effect through reverse cholesterol transport (24, 25) . HDL traps free cholesterol at the cell surface followed by reesterification and incorporation into the HDL core. Incorporated cholesterol is transferred and delivered to liver cells with eventual clearance. We have recently demonstrated that apolipoprotein A-I, a main constituent protein of HDL, can stabilize PGI2 in circulating blood (9) . PGI2 has potent anti-aggregating and vasodilating activity (27) . In addition, PGI2 is known to elevate the activities of both lysosomal (acid) and cytoplasmic (neutral) CE hydrolases leading to hydrolysis of esterified cholesterol accumulated in the smooth muscle cells (3, 4) . These effects of PGI2 are thought to be mediated by increases in intracellular cyclic AMP levels. Neutral CE hydrolase is activated through phosphorylation induced by cyclic AMP-dependent protein kinase (28, 29) , whereas acid hydrolase is independent of such kinase (3) . Taken together, these findings lead us to postulate the enhancement or prolongation of PGI2-induced hydrolysis of cholesteryl esters as another mechanism of anti-atherogenic action of HDL. To prove this hypothesis, we have performed this study using cultured bovine arterial smooth muscle cells. Under the present conditions, HDL prolongs the half-life of PGI2, maintains increased cyclic AMP levels evoked by PGI2, and enhances PGI2-stimulated CE hydrolytic activities in smooth muscle cells. In the absence of PGI2, HDL itself has no effect on CE hydrolytic activity. Furthermore, enhancement of hydrolase activities was abolished in the presence ofan adenylate cyclase inhibitor, DDA, suggesting that the activities of both enzymes are strictly dependent on cyclic AMP levels. Thus, these data support our hypothesis on a new potential mechanism of the anti-atherogenic action exerted by HDL.
After stimulation with PGI2, the intracellular cyclic AMP concentration increased rapidly and reached a peak around 15 min. On the other hand, the hydrolase activities increased rather slowly with a peak around 120 min. This time lag between the peaks of cyclic AMP and enzymes may represent the time required for de novo synthesis or enzyme phosphorylation.
HDL can stimulate PGI2 production by cultured cells when arachidonic acid is provided as a substrate (29, 30) . However, it is unlikely that HDL stimulates CE hydrolase activities through this mechanism under the present conditions, because endogenous PGI2 production was inhibited with aspirin pretreatment. The possibility that HDL sis of lysosomal and cytoplasmic CE releases free cholesterol from lysosomes and cytoplasma, respectively. This free cholesterol is either reesterified in the cytoplasma by ACAT to form CE droplets again, or is transported by sterol carrier proteins to the cell surface for excretion. HDL-mediated release of unesterified cholesterol can also inhibit the activity of the intracellular esterifying enzyme, ACAT (31, 32). Therefore, HDL facilitates egress of free cholesterol from CE accumulated in the cell to the plasma membrane. Free cholesterol is trapped by HDL at the cell surface. Thus, the net effect of HDL is a decrease in the intracellular CE (33) . HDL augmented PGI2-induced cholesteryl ester depletion not only by acting as a cholesterol acceptor, but by enhancing PGI2-induced cholesteryl ester hydrolysis through stabilizing PGI2. These results suggest that HDL plays an anti-atherogenic role through the stabilization of PGI2.
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